Clearmind Medicine Inc (CMND)

2026-08-17T07:36:21.000Z - 2 days ago

Clearmind Medicine advances CMND-100 to Alcohol Use Disorder patients

Aug 13, 2026, 7:36 AM EDT - 6 days ago

Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

2026-08-11T12:36:09.000Z - 7 days ago

Clearmind Medicine reports MEAI development program permeation study results

Aug 11, 2026, 8:05 AM EDT - 7 days ago

Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery

2026-08-06T13:51:29.000Z - 12 days ago

Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study

Aug 6, 2026, 8:00 AM EDT - 12 days ago

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study

Aug 3, 2026, 8:02 AM EDT - 15 days ago

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

2026-07-30T13:45:53.000Z - 19 days ago

Clearmind Medicine announces safety results from Part A of CMND-100 tral

Jul 30, 2026, 8:30 AM EDT - 19 days ago

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial

2026-07-28T11:55:59.000Z - 21 days ago

Clearmind Medicine completes Part A of CMND-100 trial

Jul 28, 2026, 7:47 AM EDT - 22 days ago

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

2026-07-20T12:00:09.000Z - 4 weeks ago

Clearmind files psychedelic patent application with Hong Kong Patent Office

Jul 20, 2026, 7:55 AM EDT - 4 weeks ago

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

Jul 17, 2026, 7:32 AM EDT - 4 weeks ago

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

2026-07-16T13:35:57.000Z - 4 weeks ago

Clearmind reports positive retention results for intranasal formulation of MEAI

Jul 16, 2026, 9:30 AM EDT - 4 weeks ago

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI

Jul 13, 2026, 8:17 AM EDT - 5 weeks ago

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

2026-07-10T12:41:38.000Z - 5 weeks ago

Clearmind Medicine submits response to HHS request for information

Jul 10, 2026, 8:32 AM EDT - 5 weeks ago

Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

Jul 7, 2026, 7:42 AM EDT - 6 weeks ago

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

Jun 29, 2026, 7:55 AM EDT - 7 weeks ago

Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength

2026-06-22T13:23:09.000Z - 2 months ago

Clearmind completes treatment for all participants in Part A of CMND-100 trial

Jun 22, 2026, 8:07 AM EDT - 2 months ago

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

2026-06-18T12:10:06.000Z - 2 months ago

Clearmind Medicine granted U.S. patent for Binge Behavior Regulators

Jun 18, 2026, 7:55 AM EDT - 2 months ago

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

2026-06-16T11:45:08.000Z - 2 months ago

Clearmind Medicine completes dosing for four cohorts of CMND-100 trial

Jun 16, 2026, 7:32 AM EDT - 2 months ago

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Clearmind Medicine Quarterly report: Q2 2026

Jun 5, 2026, 7:32 AM EDT - 2 months ago

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

May 29, 2026, 8:32 AM EDT - 2 months ago

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

May 26, 2026, 8:25 AM EDT - 3 months ago

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

May 19, 2026, 6:00 AM EDT - 3 months ago

Clearmind Medicine Announces 1-for-10 Reverse Share Split

May 18, 2026, 8:42 AM EDT - 3 months ago

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

May 15, 2026, 8:35 AM EDT - 3 months ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

May 12, 2026, 8:41 AM EDT - 3 months ago

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

May 11, 2026, 7:55 AM EDT - 3 months ago

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

May 5, 2026, 8:50 AM EDT - 3 months ago

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Clearmind Medicine Registration statement: Registration filing

Apr 27, 2026, 7:41 AM EDT - 4 months ago

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Apr 20, 2026, 4:03 PM EDT - 4 months ago

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Apr 20, 2026, 7:15 AM EDT - 4 months ago

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Apr 15, 2026, 7:30 AM EDT - 4 months ago

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Apr 14, 2026, 7:32 AM EDT - 4 months ago

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Mar 30, 2026, 8:32 AM EDT - 5 months ago

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Mar 27, 2026, 7:32 AM EDT - 5 months ago

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Mar 19, 2026, 8:45 AM EDT - 5 months ago

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Mar 17, 2026, 9:15 AM EDT - 5 months ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

Mar 16, 2026, 7:30 AM EDT - 5 months ago

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 13, 2026, 7:45 AM EDT - 5 months ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Mar 12, 2026, 5:00 PM EDT - 5 months ago

Clearmind Medicine Quarterly report: Q1 2026

Mar 11, 2026, 9:07 AM EDT - 5 months ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Mar 11, 2026, 7:30 AM EDT - 5 months ago

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 5 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPRC

Mar 4, 2026, 7:30 AM EST - 5 months ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Feb 19, 2026, 1:05 PM EST - 6 months ago

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Feb 17, 2026, 7:00 AM EST - 6 months ago

Clearmind Medicine Registration statement: Registration Filing

Feb 9, 2026, 8:17 AM EST - 6 months ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Feb 6, 2026, 7:55 AM EST - 6 months ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Feb 3, 2026, 8:00 AM EST - 7 months ago

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Jan 20, 2026, 4:20 PM EST - 7 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Jan 20, 2026, 7:00 AM EST - 7 months ago

Clearmind Medicine Annual report: Q4 2025

Jan 14, 2026, 8:55 AM EST - 7 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Dec 31, 2025, 9:10 AM EST - 8 months ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 24, 2025, 9:15 AM EST - 8 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 16, 2025, 8:45 AM EST - 8 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 12, 2025, 8:32 AM EST - 8 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment